INTRODUCTION
Fibrosis is a characteristic element of many chronic diseases and involves the replacement of functional cells with non-functional connective tissue enriched in extracellular matrix (ECM). This process can contribute to progression of the disease phenotype and loss of function. A connective tissue growth factor (CTGF/CCN2) is involved in the induction and progression of fibrosis, wound healing and scarring in several fibrodegenerative diseases (1 -3) . In most tissues, the CTGF is hardly expressed under normal conditions; however, CTGF levels are strongly correlated with the degree and severity of the fibrotic process in pathologies such as skin fibrosis (4), advanced atherosclerotic lesions (5) , lung fibrosis (6), kidney fibrosis (7), chronic pancreatitis (8) and hepatic fibrosis (9) , and also in muscular dystrophies, including Duchenne muscular dystrophy (DMD).
DMD is a genetic disorder characterized by the absence of the cytoskeletal protein dystrophin. This is recapitulated in the DMD mouse model (mdx). The absence of dystrophin leads to the loss of the anchoring of the myofibre to the basal lamina, eliciting subsequent myofibre degeneration, which in turn results in progressive loss of muscle mass, weakness and increased ECM accumulation (10, 11) . Formation of fibrotic scar tissue is observed early in skeletal muscles of DMD patients, and increases with age (12) . A CTGF is one of several factors thought to be involved in the fibrotic process that is characteristic of DMD and mdx models. CTGF levels correlate with skeletal muscle fibrosis (13 -15) , and increased CTGF mRNA levels have also been described in a dog model of DMD (16) and in mdx mice (17) . Previously, we have obtained experimental evidence that CTGF levels are further enhanced in mdx mice undergoing an exercise protocol that accelerates progression of the muscular dystrophy (18) . In DMD patients, an increased CTGF can be detected around the skeletal muscle fibres at the basal lamina, in fibres undergoing regeneration and in the interstitium between damaged muscle fibres (15) . Regarding potential cell types responsible for overexpression of CTGF in dystrophic skeletal muscle, an association has been found with activated fibroblasts (15) , but we have shown that CTGF expression can also be induced in myoblasts and myotubes resulting in an increased synthesis of several fibrotic proteins (19) . Importantly, we observed that besides its pro-fibrotic effect, the CTGF also induces dedifferentiation of skeletal muscle cells (19) , and that overexpression by adenoviral transfection of CTGF in the tibialis anterior skeletal muscle of normal mice induced fibrosis and damage to skeletal muscle fibres in a pattern resembling DMD (20) .
Clinical trials assessing treatment with intramuscular injection of myoblasts or satellite cells for regeneration of dystrophic skeletal muscle have been largely unsuccessful, which has been blamed at least in part on the poor migration of the muscle precursor cells (21) (22) (23) . It has been shown in sarcoglycan-deficient experimental muscular dystrophy that the excess of connective tissue in the dystrophic muscles forms a physical barrier impairing cell migration and efficacy of cell therapies (24) . We believe that therapy with dystrophin-competent (satellite) cells in DMD might be substantially improved by reducing the fibrotic barriers in dystrophic muscles.
Since the CTGF is critically involved in the fibrotic process, several investigators have evaluated the potential of suppression of CTGF expression (25) (26) (27) (28) (29) (30) , and confirmed that reduction of CTGF availability was associated with a decrease in fibrosis. Antifibrotic effects were also observed in response to inhibition of CTGF by treatment with several distinct antibodies (25, 31) . In particular, a fully human control immunoglobulin (IgG) anti-CTGF antibody (FG-3019, Fibrogen San Francisco, CA, USA) has been shown to attenuate fibrosis in a range of different organ fibrosis models in mice (32) . Moreover, in a Phase I trial using this antibody in patients with microalbuminuric diabetic kidney disease, the treatment was well tolerated and an improvement in albuminuria was reported (33) .
In this paper, we show that hemizygous CTGF-deficient mdx mice (mdx-Ctgf+/2) and mdx mice treated with the CTGF neutralizing antibody FG-3019 have similarly reduced fibrosis and skeletal muscle damage, as well as better preservation of skeletal muscle strength in isolated muscles. The antibody-treated mdx mice were also subjected to a test of exercise endurance, in which they showed better performance than mdx mice injected with control IgG. Moreover, muscle stem cell therapy was more effective in both the groups of mice with reduced CTGF availability.
These findings reveal the potential of targeting the CTGF to reduce disease progression and improve cell therapy in muscular DMD.
RESULTS

Genetic CTGF reduction attenuates skeletal muscle dystrophy in mdx mice
To determine the contribution of CTGF expression level to skeletal muscle dystrophy, we studied the effect of decreasing CTGF levels in mdx mice using a genetic approach. Mdx mice were crossed with mice hemizygous for CTGF (Ctgf+/2) to generate mdx-Ctgf+/2 (28). Figure 1A shows that the gastrocnemius of mdx-Ctgf+/2 mice expressed 50% of the CTGF protein levels present in mdx mice. Almost no CTGF was observed in the gastrocnemius of WT mice. This result was corroborated by immunohistochemical analyses, indicating that CTGF levels were decreased in the muscle fibres of mdx-Ctgf+/2 mice (Fig. 1B, upper) .
To assess the potential effect of diminishing CTGF, gastrocnemius histology was evaluated. Figure 1B , lower, shows a remarkable decrease in necrotic areas in mdx-Ctgf+/2 mice and a clear improvement in muscle histopathology compared with mdx mice. In addition, serum creatine kinase (CK) levels were significantly reduced in mdx-Ctgf+/2 mice compared with the mdx littermates (Fig. 1C) . The mdx-Ctgf+/2 mice exhibited no significant differences in body weight compared with WT and mdx mice (Supplementary Material, Fig. S1A ). Analysis of the diameter of gastrocnemius fibres indicated a significant increase in the minimal Feret's diameter in mdx-Ctgf+/2 mice compared with mdx animals, ranging from 40 to 70 mm (Supplementary Material, Fig. S1B ).
Since lower circulating CK levels were found in mdx-Ctgf+/2 than in mdx mice, we investigated whether sarcolemmal rupture rates and subsequent Evans blue dye (EBD) uptake was affected in mdx-Ctgf+/2 skeletal muscle. Normally, muscle fibres from mdx mice show EBD uptake after systemic injection due to membrane damage (34) . Figure 2A shows EBD fluorescence in gastrocnemius muscle fibres from WT, mdx and mdx-Ctgf+/2 animals. Less EBD uptake was observed in the muscle fibres of mdx-Ctgf+/2 mice compared to mdx. Total EBD uptake was reduced by 3.7 times (positive EBD nuclei per field: mdx; 75.8 + 14.5% versus mdx-Ctgf+/2; 20.6 + 4.6; P , 0.001), suggesting less muscle damage. Similar results in EBD uptake were observed in tibialis anterior fibres (Supplementary Material, Fig. S2A ). We studied the expression levels of two specific embryonic muscle markers that are increased during skeletal muscle regeneration in response to myofibre damage (35) . Figure 2B shows the increase in neonatal myosin in mdx gastrocnemius, which is significantly diminished in mdx-Ctgf+/2 skeletal muscle. We also detected a significant decrease in embryonic myosin protein levels (Fig. 2C ) and myogenin mRNA levels (Fig. 2D ) in mdx-Ctgf+/2 gastrocnemius compared with that in mdx mice.
We observed in mdx-Ctgf+/2 skeletal muscle considerably less damage compared with mdx animals. To evaluate if reduction of CTGF levels in the dystrophic background decreased apoptotic damage, we used TUNEL and immunohistochemistry for caspase-3 activity analyses. Figure 3A and B shows a significant decrease in the amount of TUNEL in mdx-Ctgf+/2 compared with mdx skeletal muscle. Similar results were found when caspase-3 activity was determined (Fig. 3 C) .
These results indicate that suppressing CTGF levels in mdx mice decreases muscle damage with a concomitant reduction in the activation of the regeneration process and apoptotic damage in mdx dystrophic skeletal muscle.
Genetic CTGF reduction diminishes fibrosis of dystrophic muscles
Next, we evaluated whether the decreased CTGF levels reduced fibrosis in dystrophic mice skeletal muscle. Figure 4A shows that diminishing CTGF expression in mdx mice strongly lowered the amount of collagen type I (upper panel) and of fibronectin immunoreactivity (lower panel) in the gastrocnemius compared with mdx skeletal muscle. Similar results were obtained in the tibialis anterior sections from the same animals (Supplementary Material, Fig. S2B ). Figure 4B also illustrates a decrease in collagen type III and fibronectin protein levels in the gastrocnemius of mdx-Ctgf+/2 mice compared with mdx mice, as determined by western blot analysis. Meanwhile, Figure 4C displays the quantitative analyses of the reduction of these fibrotic proteins in mdx-Ctgf+/2 skeletal muscle compared withthat of mdx. Similar results were observed in the tibialis anterior (Supplementary Material, Fig. S2C ).
Total mRNA was isolated from the skeletal muscle of WT, mdx and mdx-Ctgf+/2 mice. The expression levels of CTGF, fibronectin and a-SMA, a characteristic marker of myofibroblasts Figure 1 . Decreased CTGF levels in mdx mice improve skeletal muscle histology and decrease creatine kinase circulating levels. (A). Protein extracts from the gastrocnemius muscle were obtained from WT, mdx and mdx-Ctgf+/2 mice. CTGF levels were evaluated by western blot analysis. GAPDH levels are shown as loading control. Molecular weight markers are shown in kilodalton. (B). Upper, CTGF was detected by indirect immunohistochemical analysis in cryosections of gastrocnemius muscle from WT, mdx and mdx-Ctgf+/2 mice. Nuclei were labeled with haematoxylin. Bar corresponds to 50 mm. Lower, histological analysis of gastrocnemius from WT, mdx and mdx-Ctgf+/2 mice. Muscle cross sections were stained with haematoxylin and eosin to visualize the muscle architecture. Bar corresponds to 200 mm. In (A and B) , the images are representative of three independent experiments, using three mice for each experimental condition. (C). Creatine kinase activity in plasma obtained from WT, mdx and mdx-Ctgf+/2 mice. Values are expressed as mean + standard deviation (SD) of three independent experiments, using three mice for each experimental condition. #, P , 0.05 relative to WT; &, P , 0.05 relative to mdx. (36) , were determined by a qPCR. Supplementary Material, Figure S3 , shows reduced levels of fibronectin and a-SMA mRNA in mdx-Ctgf+/2 mice compared with mdx ones confirming the effects of decreased fibrosis in mdx-Ctgf+/2 skeletal muscle. A reduction in fibrosis, determined by indirect immunocytolocalization of collagen III, was observed in 8 months old mdx-Ctgf+/2 mice (Supplementary Material, Fig. S4A ). These results strongly suggest that reducing CTGF expression in the skeletal muscles of dystrophic mice decreases the extent of muscle fibrosis.
Treatment with a CTGF neutralizing antibody reduces both fibrosis of dystrophic muscle and plasma CK levels
We observed that muscle damage and fibrosis were reduced in the skeletal muscle of dystrophic mice hemizygous for the CTGF, suggesting the potential use of targeting CTGF in the treatment of DMD patients and diminishing the progress of muscle damage and fibrosis observed in the disease. For this, we decided to evaluate the use of a blocking monoclonal antibody against the CTGF (FG-3019) (37, 38) . To study the effect of blocking CTGF activity in vivo, we systemically administered FG-3019 in mdx mice for 2 months; as a control group, mdx mice were injected with control IgG.
FG-3019 treatment of dystrophic mice resulted in better preservation of skeletal muscle histology when compared with mdx mice treated with control IgG (Fig. 5A, upper panel) . Next, we evaluated the range of the fibre diameters under these experimental conditions. We found an increase in the minimal Feret's diameter in the gastrocnemius of mdx mice treated with FG-3019 compared with mdx mice treated with control IgG (50 -70 mm) (Supplementary Material, Fig. S5 ). These results indicate that systemic administration of an anti-CTGF antibody to dystrophic mice improved the dystrophic skeletal muscle architecture.
To evaluate the effect of FG-3019 on fibrosis in skeletal muscle, we determined ECM protein levels in the gastrocnemius. Decreased levels of collagen I ( . Embryonic myosin protein levels were detected by western blot analysis in extracts obtained from the gastrocnemius muscle of WT, mdx and mdx-Ctgf+/2 mice. GAPDH protein levels are shown as the loading control. Molecular weight markers are shown in kilodalton. In (A-C), the images are representative of three independent experiments, using three mice for each experimental condition. (D). mRNA levels of myogenin were determined by Reverse transcriptase-quantitative PCR using GAPDH as the reference gene. Values correspond to the mean of dCT value + SD of three independent experiments, using three mice for each experimental condition and normalized against the levels of WT mice. treated with FG-3019 compared with those injected with IgG. Quantification by densitometric analysis indicated that the decrease in collagen III and fibronectin in the muscle of mice treated with FG-3019 was 50% of that of the muscle of IgGtreated mdx mice ( Fig. 5B and C) . A reduction in fibrosis, determined by indirect immunocytolocalization of fibronectin, was also observed in 8 months old mdx mice treated for 5 months with FG-3019 compared with control mdx with IgG (Supplementary Material, Fig. S4B ).
To evaluate the effect of FG-3019 on gastrocnemius damage in mdx mice, plasma CK levels were determined. FG-3019 treatment resulted in a significant decrease in CK activity of 40% compared with control mdx mice treated with IgG (Fig. 5D ). This suggests less muscle fibre damage in the FG-3019-treated animals. Thus, blocking CTGF activity decreases fibrosis and skeletal muscle damage.
Skeletal muscle strength is higher in mdx mice with reduced CTGF availability
Since the skeletal muscles of mdx-Ctgf+/2 mice had less damage and fibrosis, we decided to evaluate the muscle contractile strength. The gastrocnemius isolated from mdx mice demonstrated a significant decrease in muscle strength compared with wild-type (WT) mouse muscle (Fig. 6A) , as previously described (39,40). Compared with mdx-Ctgf+/+ mice, gastronemius muscle from mdx-Ctgf+/2 mice had an 46% higher normalized-specific isometric force as a function of the stimulus frequency (between 40 and 80 Hz), as well as enhanced tetanicspecific force (Fig. 6B ), Thus, a lower level of CTGF in the gastrocnemius of mdx mice is associated with generation of a better net contractile force. Likewise, muscles of mdx mice treated with FG-3019 generated a higher isometric force compared with IgG-treated mdx mice at frequencies between 50 and 100 Hz (Fig. 6C) , while the tetanic force (Fig. 6D) was 40% higher.
To assess muscle function in vivo, we performed a functional test of exercise endurance (41, 42) . This revealed better performance of mdx mice treated with an FG-3019 CTGF-neutralizing antibody, when compared with mdx mice receiving control IgG. (Supplementary Material, Fig. S6 ).
These results indicate that CTGF suppression in dystrophic mice by FG-3019 treatment improves skeletal muscle strength and endurance.
Diminished levels of CTGF in dystrophic mice do not affect Smad-dependent TGF-b1, pERK1/2 and p38 signalling There is evidence that some of the fibrotic effects of CTGF occur downstream of TGF-b1 signalling (3, 36) . Supplementary Material, Figure S7A , shows increased levels of TGF-b1 mRNA in the gastrocnemius of mdx mice compared with WT; however, no differences were observed in TGF-b1 mRNA levels between mdx and mdx-Ctgf+/2 mice. We evaluated the Smaddependent TGF-b dependent pathway by investigating pSmad3 distribution via immunodetection. We observed that the number of pSmad3-positive nuclei was increased in the skeletal muscle of mdx and mdx-Ctgf+/2 mice when compared with WT (Supplementary Material, Fig. S7B ). Similar results were observed in the tibialis anterior (Supplementary Material, Fig. S7C ). Therefore, the decrease in CTGF in mdx gastrocnemius and tibialis anterior muscles did not affect the number of pSmad3-positive nuclei. Finally, we determined pSmad3 protein levels in the gastrocnemius extracts of WT, mdx and mdx-Ctgf+/2 animals (Supplementary Material, Fig. S7D ). The protein levels of pSmad3 were equally increased in mdx and mdx-Ctgf+/2 mice when compared to WT. No changes were observed in the levels of pERK1/2 and p38 in mdx compared with mdx-Ctgf+/2 mice, despite the increase when compared with WT mice (Supplementary Material, Fig. S8A -D) . These results together suggest that the decreased CTGF levels do not affect the increased Smad-dependent TGF-b1, pERK1/ 2 and p38 signalling pathway observed in dystrophic muscles.
CTGF reduction improves exogenous grafting of WT muscle stem cell in mdx mice
It is thought that excessive fibrosis in the muscles of patients with DMD (or other muscular dystrophies) impedes successful cell therapy aiming to restore dystrophin expression. To assess this, freshly purified satellite cells from isolated single myofibres of WT mice donors were grafted by intramuscular injection into the left and right tibialis anterior muscles of 7-month-old mdx and mdx-Ctgf+/2 mice (Fig. 7A) , as well . Collagen III and fibronectin protein levels were detected by western blot analysis in extracts obtained from the gastrocnemius muscle of WT, mdx and mdx-Ctgf+/2 mice. GAPDH protein levels are shown as the loading control; molecular weight markers are shown in kilodalton. In (A and B) , the images are representative of three independent experiments, using three mice for each experimental condition. (C). Densitometric analysis of western blots shown in (B). Values correspond to mean + SD of three independent experiments, using three mice for each experimental condition. #, P , 0.05 relative to WT; &, P , 0.05 relative to mdx.
as in mdx mice treated with FG-3019 or IgG (Fig. 7C) . Four weeks later, efficiency of satellite cell transplantation was analysed by staining for dystrophin-expressing myofibres. Compared with satellite cell injected age-matched mdx Ctgf+/+ mice, mdx-Ctgf+/2 mice had significantly more dystrophinpositive fibres (Fig. 7A and B) . Similar results were obtained in mdx-Ctgf+/+ mice treated with FG-3019, with higher numbers of dystrophin-positive fibres in the muscle of FG-3019-treated mdx mice compared with that in control IgGtreated mdx mice (Fig. 7D) . GAPDH protein levels are shown as the loading control; molecular weight markers are shown in kilodalton. Densitometric analyses of western blots are shown below the gels. Values correspond to mean + SD of three independent experiments, using three mice for each experimental condition. #, P , 0.05 relative to WT; &, P , 0.05 relative to mdx. In (A-D) , the images are representative of three independent experiments, using three mice for each experimental condition. (D). Creatine kinase activity in plasma obtained from WT, mdx-IgG and mdx-FG-3019 mice. Values correspond to the mean + SD of three independent experiments, using three mice for each experimental condition. #, P , 0.05 relative to WT; &, P , 0.05 relative to mdx.
The purity of the transplanted cells was evaluated. For this, an aliquot of the cell preparation used for the transplantation assay was plated on the ECM gel. Twelve hours later, the cells were fixed and analysed for the expression of the muscle-specific transcription factors Pax7, MyoD and myogenin. Around 92% of the nuclei were positive for at least one of these two markers (data not shown). To test the survival of the grafted cells, satellite cells purified from EGFP-transgenic C57BL/6 mice were grafted by intramuscular injection into both tibialis anterior muscles of 7-month-old mdx and mdx-Ctgf+/2 mice (as shown in Fig. 7A ). The muscles were dissected immediately after injection (0 h) or after 72 h. Genomic DNA was purified and the EGFP transgene present in the grafted muscles was detected by a real-time qPCR in parallel with the gene for mouse b-actin, which acted as the control gene (43, 44) . We found that after 72 h, cell survival was identical in the mdx and mdx-Ctgf+/2 mice. In both cases, 60% of the transplanted cells died during the first 3 days, as previously described (45) (data not shown). Together, these results strongly suggest that reduced CTGF activity helps muscle stem cell therapy in dystrophic mice.
We also evaluated the levels of satellite cells in the gastrocnemius of 4-month-old WT, mdx and mdx-Ctgf+/2 mice and extensor digitorium (EDL) of 8-month-old of the same mice type. No differences were found in the level of expression of Pax-7 and the number of Pax-7-positive cells in both skeletal muscle types (Supplementary Material, Fig. S9 ). Together, these results strongly suggest that reduced CTGF activity does not affect the number of satellite cells.
DISCUSSION
In this paper, we show through genetic and physiological approaches that the CTGF is crucial in regulating the deleterious phenotype observed in the skeletal muscles of DMD. We investigated the effects of partial CTGF depletion by the systemic administration of a specific anti-CTGF monoclonal antibody to mdx mice or generating a dystrophic mouse with half of the genetic load of CTGF (mdx-Ctgf+/2). In both experimental approaches, we observed a comparable decrease of muscle damage and fibrosis, associated with increased muscular functionality and an improvement of the incorporation of dystrophinpositive muscle cells/fibres/ after intramuscular injection of satellite cells derived from WT muscle.
It has been shown that CTGF levels correlate with the degree and severity of fibrosis in a variety of diseases (2, 46, 47) . This factor is also augmented in muscular dystrophies, including DMD (11, (15) (16) (17) . However, the functional role of CTGF in skeletal muscle dystrophy is unknown.
CTGF overexpression by adenovirus transfection in normal skeletal muscle induces a transient fibrotic response, as well as increased muscle damage and a significant decrease in skeletal muscle strength (20) . In this paper, we demonstrate that reduction of CTGF availability in dystrophic mice produced the opposite effects: an improvement in tissue morphology, less fibrosis, a decrease in muscle damage and an improvement in skeletal muscle strength. It is not known how the CTGF is involved in such an aggravation of the deleterious phenotype in dystrophic skeletal muscles. One of the characteristics of dystrophic skeletal Figure 6 . Decrease in the levels or activity of CTGF increases the isometric force of skeletal muscle in dystrophic mice. Gastrocnemius muscles from WT, mdx and mdx-Ctgf+/2 mice (A and B) or of WT, control antibody-treated mdx (mdx-IgG) and FG-3019-treated mdx (mdx-FG-3019) mice (C and D) were compared for isometric-specific force (mN/mm 2 ) against stimulation frequency (Hz) (A and C) and tetanic force measured at 80 Hz (B and D). In B and D, the values are represented as the percentage of specific isometric force generated by mdx-IgG muscle. The values correspond to the mean + SD of three independent experiments, using three mice for each experimental condition (#, &, P , 0.05). muscle is that muscle fibres undergo a damaging process of apoptosis. Several lines of evidence suggest that this mechanism of cell death precedes muscle fibre necrosis (48) . Thus, mdx mouse fibres that have not yet undergone apoptosis and necrosis express Bax, caspase-3 and caspase-9 (49, 50) . Skeletal muscle overexpressing CTGF through infection with Ad-mCTGF showed elevated levels of caspase-3 prior to the appearance of regenerating markers such as embryonic myosin (20) . We found that the apoptotic process was reduced in mdx-Ctgf+/2 skeletal muscle compared with mdx mice. However, the exact mechanism is still unknown. This suggests that the CTGF might induce muscle damage through an apoptotic process.
It has been shown that the inflammatory process observed in DMD and other skeletal muscle dystrophies are mediated in part by NF-kappaB (51) (52) (53) . It has been suggested that the CTGF, like other members of the CCN family of proteins, induces an inflammatory response (54) . In cardiomyocytes and mesangial cells, the CTGF induces the expression of pro-inflammatory cytokines like TNF-a, IL6 and MCP1 (55, 56) . In vivo studies in mice have shown that systemic administration of CTGF enhances the infiltration of inflammatory cells into the renal interstitium, increasing NF-kappaB activity (57) . We have observed that also CTGF adenoviral overexpression in skeletal muscle induces a strong inflammatory response (20) . Recently, the cellular inhibitor of apoptosis 1 (cIAP1) protein was shown to be an essential regulator of canonical and non-canonical NF-kappaB signalling pathways, protecting skeletal muscle from the degenerative pathology resulting from the systemic loss of dystrophin (51) .
The Ca 2+ released during skeletal muscle contraction increases reactive oxygen species (ROS) in the mitochondria (58) , which enhances the membrane permeability of the already weak sarcolemma in mdx mice, thereby inducing muscle fibre necrosis (59) (60) (61) . Thus, the administration of the antioxidant N-acetyl-cysteine prevents this increased membrane permeability (62) . This would indicate that oxidative stress could be another important source of cellular damage produced in mdx muscle fibres. Interestingly, the CTGF also induces increased levels of ROS in some cell lines (63) (64) (65) . Studies from our laboratory indicate that ROS mediates CTGF expression in myoblasts (66) , suggesting the involvement of CTGF in ROS-induced skeletal muscle injury. Therefore, the increase of this growth factor in DMD muscles could augment either ROS and/or a pro-inflammatory reaction that might partly explain the deleterious phenotype observed in dystrophin-deficient skeletal muscles.
Fibrosis is one of the major features of dystrophic muscle. High levels of connective tissue are found in biopsies of DMD patients and in different animal models of the disease (67) (68) (69) (70) . CTGF is a protein that exerts a variety of biological processes, one of which directly mediates the accumulation of ECM proteins and promotes the development of fibrosis (1, 47, 71, 72) . It is known that TGF-b is a strong inducer of CTGF activity (19, 73) . Furthermore, it has been shown that CTGF strongly synergizes with TGF-b to induce fibrosis (32, 74, 75) . Different experimental approaches have been attempted to decrease fibrosis in dystrophic muscle and other myopathies such as Marfan syndrome, which is caused by a deficiency of extracellular fibrillin-1 protein (76, 77) . Thus, in distinct animal models of the disease including mdx mice, blocking the strong pro-fibrotic factor TGF-b not only promotes the histological recovery of muscle tissue, but also significantly decreases the levels of ECM proteins, thereby increasing muscular functionality (77 -79) . Interestingly, our results indicate that the elevated levels of pSmad3, an important TGF-b signaling mediator, observed in the mdx skeletal muscle (77) remained unaltered in both experimental approaches to decrease CTGF action, suggesting that the CTGF acts downstream of TGF-b and by itself is a critical factor modulating fibrosis independent of the elevated levels of TGF-b activity observed in the dystrophic mice. No changes were observed in the levels of pERK1/2 and p38 in the skeletal muscle of the mdx-Ctgf+/2 mice compared with mdx animals.
The decrease in fibrosis observed in the mdx-Ctgf+/2 mice or mdx animals treated with FG-3019 was associated with better preservation of muscular functionality, as evidenced by skeletal muscle force analyses and functional tests of exercise endurance. We also noted a mild hypertrophy of muscle fibres, which is not observed in mice with normal CTGF availability. Expression of myogenic factors is essential but not sufficient for successful skeletal muscle formation (80) . It has been shown that a properly organized ECM is an absolute requirement for skeletal muscle formation and maintenance (81) . Fibrosis might destabilize the interactions between skeletal muscle fibre receptors, such as integrins (82, 83) and membrane-bound heparan sulphate proteoglycans (84) (85) (86) (87) , and the surrounding basal lamina. Furthermore, among the receptors described for CTGF are integrins and heparan sulphate proteoglycans (88) (89) (90) (91) . Therefore, in mice with reduced CTGF availability, and thereby less ECM accumulation around individual fibres, better communication between muscle cells and the basal lamina might also have contributed to reduction of the dystrophic phenotype.
To date, the use of myoblast or stem cell transplantation into DMD patients has had only limited success. It is likely that increased amounts of ECM constituents accumulating around skeletal muscle fibres hamper delivery and migration of cells, thus restricting their regenerative capacity (24) (25) (26) . This is supported by the fact that locally injected fibroblasts secreting metalloproteinases reduced collagen deposition, thereby allowing efficient subsequent therapy with intra-arterial injection of WT mesoangioblasts (24) . Also in the current study, we observed 1.8 and 2.9-fold better grafting of transplanted WT satellite cells in anti-CTGF-treated mdx mice-and mdx-Ctgf+/2 mice, respectively. This might reflect not only the reduction of fibrosis, but also an improvement of the microenvironment needed for myogenesis. In previous work, we have shown that the CTGF has an important inhibitory effect on muscle differentiation evidenced by a decrease in the nuclear translocation of the early muscle regulatory factor myogenin and myosin. Remarkably, CTGF treatment of myoblasts induced their dedifferentiation, with down regulation of MyoD and desmin, two markers of committed myoblasts, together with a strong reorganization of cytoskeletal filaments (19) , thus further supporting the notion of a critical role of CTGF in both progression of fibrosis and impairment of regeneration in muscular dystrophy.
MATERIALS AND METHODS
Generation of mdx-ctgf1/2 mice C57BL/10ScSn-Dmd mdx mice (mdx mice) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). C57BL/6 mice carrying a hemizygous mutation in the CTGF gene (28) were backcrossed with C57BL/10J mice (also obtained from Jackson Laboratory) for over 10 successive generations to obtain the same background as the Dmd mdx . Ctgf+/2 mice in a C57BL/10J background were bred with homozygous Dmd mdx/mdx female mice to generate mdx-Ctgf+/2 mice and mdx Ctgf+/+ WT littermates as controls. For this study, only males were used.
All mice had free access to water and a chow diet until they were studied at 12 weeks of age and 8-month-old for specific experiments. At the end of the different treatments, the mice were anaesthetized by isofluorane gas, and the gastrocnemius or tibialis anterior muscles were dissected.
All protocols were conducted in strict accordance and with the formal approval of the Animal Ethics Committee of the Pontificia Universidad Católica de Chile.
Serum creatine kinase measurement
Mice were anaesthetized by isofluorane gas, and blood was directly transferred into microhematocrit tubes (70 ml, Fisher Scientific) from the periorbital vascular plexus. Serum was obtained by allowing the blood to clot at room temperature for 30 min followed by centrifugation at 1700g for 10 min. Serum creatine kinase (CK) was measured by the enzymatic system (Valtek, Chile) according to the manufacturer's instructions.
Evans blue dye uptake
Animals were injected with Evans blue dye (EBD) [1% in phosphate buffered saline (PBS)] and allowed to stay alive for 24 h. Mice were then sacrificed, and the gastrocnemius and tibialis anterior muscles were snap frozen in isopentane, before being sectioned into 7 mm cryosections and fixed in 4% paraformaldehyde (34) . Muscle cross-sections were visualized under a Nikon Diaphot inverted microscope, equipped for epifluorescence. The percentage of EBD-positive fibres was manually counted in a blinded manner.
Treatment with the neutralizing anti-CTGF and control IgG
A fully human monoclonal IgG antibody against CTGF (FG-3019) and non-specific human IgG control antibody were obtained from Fibrogen Inc.. They were administered intraperitoneally to 12-week-old mdx male mice at doses of 10 mg/Kg each, and three times per week for 2 months, for age-related experiments the mice were treated for 5 months. After treatment, the animals were sacrificed as described above.
RNA isolation, reverse transcription and quantitative real-time PCR
Total RNA was isolated from the gastrocnemius muscles using TRIzol (Invitrogen, USA) according to the manufacturer's instructions. Total RNA (1 mg) was reverse-transcribed into complementary DNA using random hexamers and Superscript II reverse transcriptase (Invitrogen). Taqman quantitative realtime PCRs were performed in triplicate on a Eco Real-Time PCR System (Illumina, USA), using pre-designed primer sets for mouse Myogenin, CTGF, a-SMA, fibronectin, Pax-7 and the housekeeping gene GAPDH (Taqman Assays-on-Demand, Applied Biosystems, USA). mRNA expression was quantified using the comparative DCt method (2-DDCT), using GAPDH as the reference gene. The mRNA levels were expressed relative to the mean expression in the WT mice.
TUNEL assay
TUNEL assays were performed by using an in situ cell death detection kit, with colorimetric detection of diaminobenzine chromogen (Promega, Madison, WI), all according to the manufacturers' protocols.
Immunoblot analysis
For muscle immunoblot analyses, the gastrocnemius and tibialis anterior muscles were homogenized in 10 volumes of Tris-EDTA buffer with 1 mM phenylmethylsulfonyl fluoride as described previously (20) . Briefly, proteins were determined in aliquots of muscle extracts using the Bicinchoninic Acid Protein Assay kit (Pierce, IL), with BSA as the standard. Aliquots (50 -100 mg) were subjected to sodium dodecyl sulphate gel electrophoresis in 8 or 10% polyacrylamide gels, electrophoretically transferred onto PVDF membranes (Schleicher & Schuell) and probed with specific antibodies against CTGF (Santa Cruz Biotechnology, USA), fibronectin (Sigma-Aldrich, USA), collagen III (Rockland, USA), phospho-Smad3 (pSmad3) (Ser423/425), total Smad 3 (Smad3), phospho ERK1/2, total ERK, phospho p38 and total p38 (Cell Signaling, USA), embryonic myosin (Hybridoma Bank) and GAPDH (Millipore, USA). All immunoreactions were visualized by enhanced chemiluminescence (Pierce, USA). Densitometric analysis and quantification were performed using the ImageJ software (NIH, USA).
Immunofluorescence microscopy
For muscle immunofluorescence, gastrocnemius and tibialis anterior muscles snap-frozen in isopentane were sectioned and cryosections (7 mm) were fixed in 4% paraformaldehyde, blocked for 1 h in 10% goat serum in PBS and incubated for 1 hour at room temperature with specific antibodies against fibronectin, collagen I (Chemicon, USA), embryonic myosin and neonatal myosin (Santa Cruz Biotechnology) and caspase-3 activated (Cell Signaling). As the secondary antibody, FITCconjugated goat anti-rabbit IgG and rabbit anti-mouse IgG (Thermom, USA) were used. For monoclonal anti-mouse antibodies, all the incubations were performed with mouse IgG-blocking solution from the M.O.M. kit (Vector Lab, USA) diluted in 0.01% Triton X-100/PBS. For nuclear staining, the sections were incubated with 1 mg/ml Hoechst 33258 in PBS for 10 min. After rinsing, the coverslips were mounted using Fluoromont (Dako, USA) and viewed under a Nikon Diaphot inverted microscope, equipped for epifluorescence.
Immunohistochemical staining
For immunohistochemical analysis, cryosections (7 mm) were fixed in acetone, incubated for 1 h with anti-CTGF in 5% goat serum in PBS and blocked for 15 min in methanol-H 2 O 2 (3%). After an hour of incubation with Poly-HRP anti-rabbit-IgG (Immunologic, the Netherlands), enzyme activity was measured using a 3 ′ ,3 ′ -diaminobenzidine tetrahydrochloride liquid system (Dako). Nuclei were stained with haematoxylin.
Skeletal muscle histology and determination of fibre diameter
Fresh-frozen gastrocnemius and tibialis anterior muscles were sectioned and cryosections (7 mm) were placed on glass slides. Haematoxylin and eosin staining was performed according to the standard procedures.
Fibre sizes were determined using the Image J software on five randomly captured images of the gastrocnemius stained with laminin (Sigma, USA) and Hoechst 33258. Fibres were manually selected and the minimal Feret diameter of each fibre was computed by the software.
Isolation of single mouse skeletal muscle fibres, satellite cell purification and muscle grafting
The isolation of single myofibres was undertaken essentially as described before (92) Briefly, EDL and soleus muscles from 6-week-old C57-BL10 mice were dissected and digested in 0.2% (w/v) collagenase type 1 (Sigma-Aldrich) in DMEM (Gibco, USA), supplemented with 4 mm L-glutamine (Sigma-Aldrich) and 1% penicillin and streptomycin solution (Sigma), for 90 min in a 378C water bath. Only single and stretched myofibres were collected and cultured for 30 min in a 5% CO 2 cell culture incubator before any other treatment.
Satellite cells were separated from the myofibres by physical trituration using the method of Collins et al. (92) . Briefly, the isolated intact fibres were suspended and triturated with a 1 ml syringe. The suspension was filtered to remove debris and then centrifuged. The pellet was resuspended in physiological saline (NaCl, 0.9%). To control the purity of the isolated satellite cells, an aliquot was seeded onto Matrigel (1 mg/ml) (Sigma) and cultured overnight in complete medium for 18 h before immunocytochemical identification of myogenic markers.
For the experiments in dystrophic Ctgf+/2 mice, 300 satellite cells were grafted into both tibialis anterior muscles of 7-month-old mdx and mdx-Ctgf+/2 mice under anaesthesia. After 4 weeks, both tibialis anterior muscles were processed for cryosectioning.
For the grafting experiments in mdx mice treated with anti-CTGF antibodies, 600 satellite cells were grafted into both tibialis anterior muscles of five control IgG-treated mdx mice and six FG-3019-treated mdx mice after 5 weeks of treatment. Three weeks after the satellite cell transplantation, both tibialis anterior muscles were processed for cryosectioning.
In some experiment, fibres obtained from the EDL muscles from mdx or mdx-CTGF+/2 mice were fixed in 4% paraformaldehyde immediately after the extraction and stained with a mouse monoclonal anti-Pax7 antibody (Developmental Studies Hybridoma Bank) as described previously (93) . The number of Pax-7 positive nuclei on each fibre was counted under direct observation with an inverted microscope, equipped for epifluorescence.
Analysis of the grafted satellite cell survival
The extraction of muscle genomic DNA was performed with a DNA purification kit (QIAamp system from Qiagen). The analysis of the survival rate of the grafted satellite cells was performed as previously described (44) . Briefly, extracted DNA was subjected to amplification by a real-time PCR using a TaqMan PCR Universal Master Mix on an Illumina Eco real time PCR system (Illumina). Primers and Taqman probes for EGFP and b-actin (endogenous control) were obtained from Applied Biosystems.
Contractile properties
The isometric force of isolated muscles was measured as described previously (94) . Briefly, the optimum muscle length (L o ) and stimulation voltage were determined from the micromanipulation of muscle length to produce a maximum isometric twitch force. Maximum isometric tetanic force (Po) was determined from the plateau of the frequency -force relationship after successive stimulations at 1 -200 Hz for 450 ms, with 2 min rests between the stimuli. After measuring the isometric contractile properties, muscles were subjected to a tetanic stimulation protocol that was performed three times. Muscles at L o were maximally stimulated for 450 ms once every 5 s. After functional testing, muscles were removed from the bath, trimmed of their tendons and any adhering non-muscle tissue, blotted once on a filter paper and weighed. Muscle mass and L o were used to calculate the specific net force [force normalized per total muscle fibre cross-sectional area, mN/mm 2 ].
Running test
Mice were subjected to a running test for 15 min at 15 m/min on a treadmill. The number of times the mice were moved back to the first third of the moving platform was counted.
Statistical analysis
The statistical significance of the differences between the means of the experimental groups was evaluated using one-way analysis of variance (ANOVA) with a post hoc Bonferroni multiplecomparison test (Prism 3.0, GraphPad). A difference was considered statistically significant at P -value ,0.05.
